![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://lookaside.fbsbx.com/lookaside/crawler/threads/DWmuLpvEprC/0/image.jpg)
glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]
USD22.21
USD52.21
Pay in 4 interest-free payments of $5.55 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1_ra_infographic.png)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10555-024-10192-9/MediaObjects/10555_2024_10192_Fig1_HTML.png)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://www.frontiersin.org/files/Articles/1483792/xml-images/fphar-15-1483792-g001.webp)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs44355-026-00069-9/MediaObjects/44355_2026_69_Fig1_HTML.png)
![glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_ra_pharmacology [TUSOM | Pharmwiki]](https://cdn2.caymanchem.com/cdn/cms/caymanchem/PublishingImages/Lists/NewsItems/AllItems/Summary%20of%20insulin%20and%20glucagon%20pathways%20in%20glucose%20homeostasis.png)
.webp)
